BackSinopharm Group Ltd. Overview

Sinopharm Group Ltd. Other Current Liabilities

Track Sinopharm Group Ltd.'s other current liabilities ($59B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$59.04B
↑ 43.31% YoYΔ $17.84B vs prior year quarter

Peer trimmed avg / median

Loading

Sinopharm Group Ltd. Other Current Liabilities History

Loading

Sinopharm Group Ltd. vs. peers: Other Current Liabilities Comparison

Loading

Sinopharm Group Ltd. Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Sinopharm Group Ltd. (SHTDF) FAQ

As of the most recent data (June 2026), SHTDF shows a other current liabilities of $59B. That compares with $41B in the prior-year period — up 43.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SHTDF's other current liabilities is now $59B (was $41B) — a 43.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Sinopharm Group Ltd. is outperforming or lagging.

Tracking SHTDF's other current liabilities over time shows whether Sinopharm Group Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $59B That compares with $41B in the prior-year period — up 43.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Sinopharm Group Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $59B) with ownership activity and broader fundamentals.